Inmode (DE:154)
NASDAQ:154
154 Stock Chart & Stats
€11.99
€0.39(2.41%)
At close: 4:00 PM EST
€11.99
€0.39(2.41%)
Day’s Range― - ―
52-Week Range€11.02 - €13.88
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€741.21M
Enterprise Value€493.12M
Total Cash (Recent Filing)€537.16M
Total Debt (Recent Filing)€4.83M
Price to Earnings (P/E)9.8
Beta0.51
Next Earnings
Jul 23, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares Outstanding63,358,750
10 Day Avg. Volume0
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.39
Price to Sales (P/S)2.56
P/FCF Ratio11.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.56Price Target Upside13.11% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)1.15
Revenue Forecast (FY)€318.64M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity/cash base provide durable financial flexibility. This supports capital returns, R&D or opportunistic M&A, and lets the company weather cyclical demand in aesthetics without forcing distressed asset sales or emergency financing.
High-Quality Cash GenerationNear one-to-one conversion of net income to free cash flow indicates cash quality and repeatable internal funding. Reliable cash generation underpins buybacks, reinvestment in product development, and service/support for the installed base, strengthening long-term resilience.
Product Platform & Installed-Base MomentumBroadening platform portfolio and pipeline FDA filings expand addressable procedures and drive capital sales. A growing installed base from diversified devices supports recurring consumable and service revenue, improving revenue durability even if device sales cycle.
Bears Say
Multi-year Revenue SlowdownSustained revenue declines over multiple years weaken installed-base growth and slow future consumable pull-through. A smaller growth runway limits operating leverage and makes sustained margin recovery harder without material market or product-driven demand improvement.
Margin CompressionMaterial compression in gross and operating margins reduces cashflow available for reinvestment and returns. If newer platforms or higher product mix/discounting continue to erode margins, the company's high-profitability structural advantage may be harder to sustain long term.
Leadership & Governance TurnoverSenior finance and board turnover during a reorganization and recovery phase raises execution risk on cost controls, guidance delivery, and capital allocation. Combined with prior failed sale attempts and a securities class action, governance disruptions could slow strategic initiatives.
InMode News
154 FAQ
What was Inmode’s price range in the past 12 months?
Inmode lowest stock price was €11.02 and its highest was €13.88 in the past 12 months.
What is Inmode’s market cap?
Inmode’s market cap is €741.21M.
When is Inmode’s upcoming earnings report date?
Inmode’s upcoming earnings report date is Jul 23, 2026 which is in 44 days.
How were Inmode’s earnings last quarter?
Inmode released its earnings results on May 06, 2026. The company reported €0.215 earnings per share for the quarter, missing the consensus estimate of €0.257 by -€0.041.
Is Inmode overvalued?
According to Wall Street analysts Inmode’s price is currently Undervalued.
Does Inmode pay dividends?
Inmode does not currently pay dividends.
What is Inmode’s EPS estimate?
Inmode’s EPS estimate is 0.29.
How many shares outstanding does Inmode have?
Inmode has 63,358,750 shares outstanding.
What happened to Inmode’s price movement after its last earnings report?
Inmode reported an EPS of €0.215 in its last earnings report, missing expectations of €0.257. Following the earnings report the stock price went down -0.455%.
Which hedge fund is a major shareholder of Inmode?
Currently, no hedge funds are holding shares in DE:154
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InMode Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€13.56 (13.11% Upside)
€13.56 (13.11% Upside)
Blogger Sentiment
Bullish
DE:154 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.66%
12-Months-Change
Fundamentals
Return on Equity
13.28%
Trailing 12-Months
Asset Growth
6.54%
Trailing 12-Months
Company Description
Inmode
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
154 Company Deck
154 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained a mix of modest top-line progress and strategic positives (5% revenue growth, strong cash balance, product launches, sales reorganization and share repurchases) offset by notable margin compression, rising operating expenses and declines in EPS. Management provided steady full-year guidance and described early signs of stabilization in the U.S., but profitability pressures and macroeconomic headwinds temper the outlook. International and product development initiatives offer upside, while near-term margin and demand uncertainty are the primary negatives.View all DE:154 earnings summaries154 Stock 12 Month Forecast
Average Price Target
€13.56
▲(13.11% Upside)
Technical Analysis
Orthofix Medical
―
AxoGen
―
Establishment Labs Holdings
―
SS Innovations International
―
Bioventus
―
Options Prices
Currently, No data available
---